期刊文献+

蛇床子素对B-ALL 697细胞的抗肿瘤作用及其机制 被引量:3

Antitumor effec t of osthole on human B-cell acute lymphoblastic leukemia 697 cells and its mechanism
原文传递
导出
摘要 目的 :探讨蛇床子素对人急性B淋巴细胞白血病(B-cell acute lymphoblastic leukemia,B-ALL)697细胞的抗肿瘤作用及其可能的作用机制。方法 :不同浓度(8、16、32、64和128μmol/L)蛇床子素处理B-ALL697细胞后,采用CCK-8法检测细胞的增殖抑制率。8和32μmol/L蛇床子素处理B-ALL 697细胞后,采用FCM法检测细胞凋亡率,应用实时荧光定量PCR和蛋白质印迹法检测凋亡相关分子Bcl-2和Bax mRNA及蛋白的表达。8和32μmol/L蛇床子素单独或联合自噬抑制剂3-甲基腺嘌呤(3-methyladenine,3-MA)处理B-ALL 697细胞后,进行单丹磺酰戊二胺(monodansylcadaverine,MDC)染色,FCM法检测细胞内平均荧光强度(meanuorescence intensity,MFI),以此反映B-ALL 697细胞的自噬情况;应用实时荧光定量PCR和蛋白质印迹法检测自噬相关分子Beclin 1 mRNA及蛋白的表达。结果 :8、16、32、64和128μmol/L蛇床子素处理组B-ALL 697细胞增殖被明显抑制,且呈剂量和时间依赖性(P值均<0.05)。8和32μmol/L蛇床子素处理组B-ALL 697细胞凋亡率明显上升(P值均<0.01),凋亡相关分子Bax mRNA及蛋白表达水平明显升高,Bcl-2 mRNA及蛋白表达水平明显下降(P值均<0.05)。8和32μmol/L蛇床子素处理组B-ALL697细胞中MDC MFI明显增加(P值均<0.01),自噬相关分子Beclin 1 mRNA及蛋白表达水平均明显升高(P值均<0.05);3-MA联合蛇床子素处理组细胞内MDC MFI无明显变化,Beclin 1 mRNA及蛋白表达水平均无明显变化(P值均> 0.05)。结论 :蛇床子素通过抑制B-ALL 697细胞增殖,诱导细胞凋亡和自噬,发挥抗肿瘤作用。促凋亡机制可能与Bax表达上调和Bcl-2表达下调有关,Beclin 1参与了细胞自噬过程。 Objective: To investigate the antitumor effect of osthole on human B-cell acute lymphoblastic leukemia(B-ALL) 697 cells and its possible mechanism.Methods: After B-ALL 697 cells were treated with different concentrations(8, 16, 32, 64 and 128 μmol/L) of osthole, the inhibition rate of cell proliferation was detected by CCK-8 assay. After B-ALL 697 cells were treated with 8 and 32 μmol/L osthole, the apoptosis was detected by FCM, the expressions of apoptosis-associated molecule Bcl-2 and Bax were detected by real-time fluorescent quantitative PCR and Western blotting. After B-ALL 697 cells were treated with 8 and 32 μmol/L osthole alone or in combination with autophagy inhibitor 3-methyladenine(3-MA), the intracellular mean fluorescent intensity(MFI) was detected by FCM [stained by monodansylcadaverine(MDC)] to reflect the autophagy. The expressions of autophagy-associated molecule Beclin 1 mRNA and protein was detected by real-time fluorescent quantitative PCR and Western blotting, respectively. Results: The proliferation of B-ALL 697 cells in 8, 16, 32, 64 or 128 μmol/L osthole treatment group was significantly inhibited in a dose-and time-dependent manner(all P < 0.05). The apoptosis rate of B-ALL 697 cells in 8 or 32 μmol/L osthole treatment group was significantly increased(both P < 0.01), the expression levels of Bax mRNA and protein were increased(all P < 0.05), while the expression levels of Bcl-2 mRNA and protein were decreased(all P < 0.05). The MDC MFI of B-ALL 697 cells in 8 or 32 μmol/L osthole treatment group was increased(both P < 0.01), and the expression levels of Beclin 1 mRNA and protein were significantly increased(all P < 0.05). There was no significant change in MDC MFI and the expressions of Beclin 1 mRNA and protein after treatment with 3-MA in combination with osthole(all P > 0.05).Conclusion: Osthole inhibits the proliferation, and induces the apoptosis and autophagy of B-ALL 697 cells. The mechanism of promoting apoptosis may be related to the up-regulation of Bax expression and the down-regulation of Bcl-2 expression. Beclin 1 participates in the autophagy.
作者 朱聪 贾秀红 刘迎雪 王红 ZHU Cong;JIA Xiuhong;LIU Yingxue;WANG Hong(Department of Pediatrics,Affiliated Hospital of Binzhou Medical University,Binzhou 256603,Shandong Province,China)
出处 《肿瘤》 CAS CSCD 北大核心 2019年第2期91-98,共8页 Tumor
关键词 白血病 实验性 细胞增殖 细胞凋亡 自噬 蛇床子素 Leukemia,experimental Cell proliferation Apoptosis Autophagy Osthole
  • 相关文献

参考文献1

二级参考文献20

  • 1Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update[J]. J Clin Oncol, 2011, 29(5):551-565.
  • 2Henze G, v Stackelberg A, Eckert C. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia[J]. Kiln Padiatr, 2013,225(Suppl 1):$73-78.
  • 3Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial[J]. Lancet, 2010, 376(9757):2009-201 7.
  • 4Li B, Li H, Bai Y, et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL[J]. Nat Med, 201 5, 21 (6):563-571.
  • 5Innocenti F, Danesi R, Di Paolo A, et al. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate[j]. Cancer Chemother Pharmacol, 1996, 37(5):409-414.
  • 6Giverhaug T, Loennechen T, Aarbakke J. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX)LI]. Gen Pharmacol, 1999, 33(4):341-346.
  • 7Balls FM, Holcenberg JS, Zimm S, et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine[J]. C/in Pharmacol ?-her, 1987, 41 (4):384-387.
  • 8BokkerinkJP, Bakker MA, Hulscher TW, et al. Sequence-, time- and dose- dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts[j]. Biochem Pharmacol, 1986, 35(20):3549-3555.
  • 9Bokkerink JP, Damen FJ, Hulscher MW, et al. Biochemical evidence for synergistic combination treatment with methotrexate and 6-mercaptopurine in acute lymphoblastic leukemia[J]. Haematol Blood Transfus, 1990, 33:110-117.
  • 10Ashwanikumar N, Kumar NA, Nair SA, et al. Dual drug delivery of 5-fluorouracil (5-FU) and methotrexate (MTX) through random copolymeric nanomicelles of PLGA and polyethylenimine demonstrating enhanced cell uptake and cytotoxicityLI]. Colloids Surf B Biointerfaces, 2014, 122:520-528.

共引文献3

同被引文献52

引证文献3

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部